OA09908A - Treatment of neoplastic disease with interleukin-10 - Google Patents

Treatment of neoplastic disease with interleukin-10

Info

Publication number
OA09908A
OA09908A OA60389A OA60389A OA09908A OA 09908 A OA09908 A OA 09908A OA 60389 A OA60389 A OA 60389A OA 60389 A OA60389 A OA 60389A OA 09908 A OA09908 A OA 09908A
Authority
OA
OAPI
Prior art keywords
interleukin
treatment
neoplastic disease
patient
effective amount
Prior art date
Application number
OA60389A
Other languages
English (en)
Inventor
Paulo J M Vieira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of OA09908A publication Critical patent/OA09908A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
OA60389A 1991-01-16 1993-07-07 Treatment of neoplastic disease with interleukin-10 OA09908A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64134791A 1991-01-16 1991-01-16

Publications (1)

Publication Number Publication Date
OA09908A true OA09908A (en) 1994-09-15

Family

ID=24571976

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60389A OA09908A (en) 1991-01-16 1993-07-07 Treatment of neoplastic disease with interleukin-10

Country Status (18)

Country Link
EP (1) EP0567576B1 (de)
JP (1) JP3260368B2 (de)
KR (1) KR100207766B1 (de)
AT (1) ATE116550T1 (de)
AU (1) AU652030B2 (de)
CA (1) CA2100553A1 (de)
CZ (1) CZ282523B6 (de)
DE (1) DE69201128T2 (de)
DK (1) DK0567576T3 (de)
ES (1) ES2068705T3 (de)
FI (1) FI933193A0 (de)
GR (1) GR3015510T3 (de)
HK (1) HK192196A (de)
HU (1) HU218598B (de)
NO (1) NO310444B1 (de)
OA (1) OA09908A (de)
SK (1) SK279556B6 (de)
WO (1) WO1992012725A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
RU2120802C1 (ru) * 1992-08-20 1998-10-27 Шеринг Корпорейшн Фармацевтическая композиция, предназначенная для торможения зависимой от интерлейкина-2 пролиферации опухолевых клеток, увеличения содержания интерферона, лечения воспалительных заболеваний кишечника, потенцирования торможения производства цитокина и ограничения или торможения аллергической реакции замедленного типа
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
NZ259584A (en) * 1994-01-20 1998-01-26 Schering Corp Cancer treatment using interleukin 10 activated peripheral blood mononuclear cells optionally combined with il-10 alone or in combination with il-2 or alpha interferon (alpha-ifn), to stimulate peripheral blood mononuclear cells
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
WO2001005821A2 (en) * 1999-07-16 2001-01-25 Maria Teresa Bejarano Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis
EP2295450B1 (de) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegyliertes interleukin 10
EP2066336B1 (de) 2006-09-28 2012-09-19 Merck Sharp & Dohme Corp. Verwendung von pegyliertem il-10 zur krebsbehandlung
ES2655364T3 (es) 2008-12-17 2018-02-19 Merck Sharp & Dohme Corp. Producción de IL-10 mono- y dipegilada y sus usos
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (de) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Verfahren zur beurteilung der proteinidentität und -stabilität
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
ZA9010188B (en) * 1989-12-20 1991-08-28 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma

Also Published As

Publication number Publication date
CA2100553A1 (en) 1992-07-17
JP3260368B2 (ja) 2002-02-25
HK192196A (en) 1996-10-25
HUT69962A (en) 1995-09-28
FI933193A7 (fi) 1993-07-14
ATE116550T1 (de) 1995-01-15
NO310444B1 (no) 2001-07-09
CZ141293A3 (en) 1994-01-19
ES2068705T3 (es) 1995-04-16
EP0567576B1 (de) 1995-01-04
SK74793A3 (en) 1995-03-08
EP0567576A1 (de) 1993-11-03
DE69201128D1 (de) 1995-02-16
DE69201128T2 (de) 1995-05-24
FI933193L (fi) 1993-07-14
NO932570D0 (no) 1993-07-15
GR3015510T3 (en) 1995-06-30
HU9302066D0 (en) 1993-11-29
FI933193A0 (fi) 1993-07-14
NO932570L (no) 1993-07-15
JPH06504785A (ja) 1994-06-02
AU1261792A (en) 1992-08-27
DK0567576T3 (da) 1995-06-12
AU652030B2 (en) 1994-08-11
CZ282523B6 (cs) 1997-07-16
WO1992012725A1 (en) 1992-08-06
SK279556B6 (sk) 1998-12-02
HU218598B (hu) 2000-10-28
KR100207766B1 (ko) 1999-07-15

Similar Documents

Publication Publication Date Title
GR3015510T3 (en) Treatment of neoplastic disease with interleukin-10.
EG19304A (en) Method of treating pre-menstrual syndrome
EP0553291A4 (en) Treatment of autoimmune diseases by oral administration of autoantigens
ZA913282B (en) Dosage form
EP0292172A3 (en) Apparatus for thermal treatment of body tissue
EP0102534A3 (en) Hair-growing agent
IE900250L (en) Immunogenic compositions against gastrin peptides
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
GR3029670T3 (en) Treatment of macular degeneration.
HU891056D0 (en) Process for treating the diseases of the gullet and the stomach-intestine system
IL83775A0 (en) Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
SG45366A1 (en) Method of treating and/or diagonising soft tissue tumors
ZA886459B (en) Use of bezafibrate for treating diabetes
MY104521A (en) Treatment of depression.
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
PL277464A1 (en) Apparatus for surgical treatment of ametropia
HU900381D0 (en) Process for producing medical preparatives utilizable for treating cancerous diseases
HUT64478A (en) Process for producing medical preparatives for treatment of b-cell tumours
PL283664A1 (en) Therapeutical set for treating limb bone fractures by traction
Shust 10-year results of programmed treatment of Hodgkin's disease patients
EP0267402A3 (en) Use of follicle regulatory protein for the production of a therapeutic agent for the treatment of neoplasm of gonadal origin
IL68896A0 (en) Medicine for treatment of neoplastic diseases
IT1243947B (it) 2-azido-ornitina, sua preparazione e suo impiego in terapia
RU93046326A (ru) Способ лечения медикаментозных эзофаго-гингиво-стоматитов